BioSpace News Archive

Collaboration to address rise in global weed resistance using Corteva’s product discovery and development expertise and AgPlenus’ internal novel herbicide pipeline

Precision Spine, Inc., a medical device company dedicated to Made-in-the-USA manufacturing, has nationally launched the Reform POCT (Posterior Occipital Cervical Thoracic) System, which is a posterior spinal fixation system that offers surgeons the versatility and flexibility necessary to achieve stability in the occiput, cervical and thoracic spine (Occiput-T3) when engaging in spine fusion.

March 25, 2020 12:00 UTC X4 Pharmaceuticals to Host 2020 Analyst Day Webinar: A Deep Dive into WHIM Syndrome - Virtual event to be held on Tuesday, April 7, 2020 at 8:00 a.m. ET - CAMBRIDGE, Mass.--( BUSINESS WIRE )-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will host a virtual Analyst Day to discuss its strateg

ENHERTU ® Approved in Japan for Treatment of Patients with HER2 Positive Unresectable or Metastatic Breast Cancer Approval based on the pivotal DESTINY-Breast01 trial represents third approval ever under the conditional early approval system in Japan, and follows recent U.S. accelerated approval of ENHERTU ® ENHERTU ® represents the second innovative treatment from the oncology pipeline of Daiichi Sankyo to be approved for use in Japan in past

Name Change Emphasizes Company Vision and Mission to Combat Cancer -

Moderna, Inc., (Nasdaq: MRNA) today announced that Stéphane Bancel, Chief Executive Officer will participate in the MIT Laboratory for Financial Engineering (LFE) and Golub Center for Finance and Policy (GCFP) Distinguished Lecture Series, “Dealing with Coronavirus: An Industry Perspective” on Wednesday, April 1 from 4:30-6:00 p.m. EDT.

A study evaluating endoscopic procedure time removing complex colorectal polyps shows superiority of DiLumen over control group. WESTPORT, Conn.--( BUSINESS WIRE )-- Connecticut-based medical device innovator Lumendi, LLC ( www.lumendi.com ) reports that its 1:1 randomized trial of the DiLumen Endolumenal Interventional Platform (EIP) successfully met the primary endpoint of an IRB-approved 200-patient prospective study. The study evaluates DiLumen’

Masimo (NASDAQ: MASI) today announced the results of a recently published ten-year retrospective study in which researchers at Dartmouth-Hitchcock Medical Center investigated the impact of an integrated clinical surveillance monitoring system, using Masimo SET® and Patient SafetyNet™ technologies, on mortality related to use of prescribed opioids in the general ward.

NTT Research PHI Lab Director to Support Coherent Ising Machines (CIMs) Initiative

Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that its Board of Directors has decided to explore potential financial and strategic alternatives intended to enhance stockholder value. The Company has engaged Canaccord Genuity LLC as its financial advisor. Th